---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033845"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T05:17:23.850624+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma Q2 2023 net loss $1.5M; cash $40.2M; strategic review continues

## Summary
- Net loss $1.5M ($0.10/sh) vs $3.1M ($0.22) in Q2 2022; total operating expenses $2.0M vs $3.2M.
- Cash and equivalents $40.2M at June 30, 2023; expected to fund operations through end of 2024.
- R&D expenses fell to $0.3M from $1.5M due to rNAPc2 trial closeout and 67% workforce reduction in July 2022.
- Strategic review process ongoing with Ladenburg Thalmann; no defined timeline or guarantee of transaction.

## SEC filing metadata
- accession: 0000950170-23-033845
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/0000950170-23-033845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/abio-20230721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033845
- JSON: https://secwatch.observer/filing/0000950170-23-033845.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033845.txt

## Key facts
- Earnings Releases
  Oruka Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $1.5 million, EPS $0.10 per basic and diluted share.
  - Period: the quarter ended June 30, 2023
  - Net income: $1.5 million
  - EPS: $0.10 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended June 30, 2023 was $1.5 million, or $0.10 per basic and diluted share, compared to $3.1 million, or $0.22 per basic and diluted share in the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/0000950170-23-033845-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.